Sucralfate significantly reduces ciprofloxacin concentrations in serum

Antimicrob Agents Chemother. 1990 May;34(5):931-3. doi: 10.1128/AAC.34.5.931.

Abstract

The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 micrograms.h/ml by sucralfate (P less than 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 micrograms/ml (P less than 0.005). We conclude that concurrent ingestion of sucralfate significantly reduces the concentrations in serum produced by a 500-mg dose of ciprofloxacin. On the basis of these findings, ciprofloxacin and sucralfate should not be administered concurrently.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Availability
  • Ciprofloxacin / blood*
  • Depression, Chemical
  • Drug Interactions
  • Female
  • Humans
  • Male
  • Random Allocation
  • Sucralfate / pharmacology*

Substances

  • Sucralfate
  • Ciprofloxacin